- Home
- MCI vs MNPR Comparison
MCI vs MNPR Comparison
Compare MCI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCI
- MNPR
- Stock Information
- Founded
- MCI 1971
- MNPR 2014
- Country
- MCI United States
- MNPR United States
- Employees
- MCI N/A
- MNPR N/A
- Industry
- MCI Trusts Except Educational Religious and Charitable
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- MCI Finance
- MNPR Health Care
- Exchange
- MCI Nasdaq
- MNPR Nasdaq
- Market Cap
- MCI 419.4M
- MNPR 390.5M
- IPO Year
- MCI N/A
- MNPR 2019
- Fundamental
- Price
- MCI $20.38
- MNPR $100.16
- Analyst Decision
- MCI
- MNPR Strong Buy
- Analyst Count
- MCI 0
- MNPR 12
- Target Price
- MCI N/A
- MNPR $89.82
- AVG Volume (30 Days)
- MCI 40.4K
- MNPR 78.9K
- Earning Date
- MCI 01-01-0001
- MNPR 11-07-2025
- Dividend Yield
- MCI 8.46%
- MNPR N/A
- EPS Growth
- MCI N/A
- MNPR N/A
- EPS
- MCI 1.82
- MNPR N/A
- Revenue
- MCI N/A
- MNPR N/A
- Revenue This Year
- MCI N/A
- MNPR N/A
- Revenue Next Year
- MCI N/A
- MNPR N/A
- P/E Ratio
- MCI $9.88
- MNPR N/A
- Revenue Growth
- MCI N/A
- MNPR N/A
- 52 Week Low
- MCI $12.96
- MNPR $4.50
- 52 Week High
- MCI $19.24
- MNPR $105.00
- Technical
- Relative Strength Index (RSI)
- MCI 42.44
- MNPR 88.01
- Support Level
- MCI $20.44
- MNPR $72.41
- Resistance Level
- MCI $20.82
- MNPR $105.00
- Average True Range (ATR)
- MCI 0.60
- MNPR 7.18
- MACD
- MCI -0.10
- MNPR 2.83
- Stochastic Oscillator
- MCI 9.22
- MNPR 88.40
About MCI Barings Corporate Investors
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.